Sandy Calvin

Sandy Calvin has extensive work experience in the accounting field. They began their career at Deloitte & Touche as a Staff Auditor from 1988 to 1990. They then moved on to Vical, Inc. as an Associate Director Accounting, where they worked from an unknown start date until 2004. At Amylin Pharmaceuticals Inc., Sandy held the role of Director, Accounting Operations from 2004 to 2012. Following this, they worked at Amylin Pharmaceuticals LLC, a subsidiary of Bristol-Myers Squibb, as Director, San Diego Site Controller from 2012 to 2014. Sandy then transitioned to Amylin Pharmaceuticals LLC, now a subsidiary of AstraZeneca, as Director, San Diego Site Controller until October 2014. They have since been with Travere Therapeutics, initially as an Executive Director, Corporate Controller from 2014 to 2018, then as Vice President, Corporate Controller from 2018 to 2021. Currently, Sandy holds the position of Vice President, Corporate Controller & Chief Accounting Officer at Travere Therapeutics, a role they have held since September 2021. They were promoted to Senior Vice President, Chief Accounting Officer in April 2022, and are currently in that role.

Sandy Calvin earned a Bachelor's degree in Accounting from San Diego State University between 1983 and 1987.